104 related articles for article (PubMed ID: 3678326)
21. Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats.
Nagata M; Hidaka Y; Hatakeyama K; Kawano Y; Iwakiri T; Okumura M; Arimori K
Biopharm Drug Dispos; 2011 Mar; 32(2):126-30. PubMed ID: 21341281
[TBL] [Abstract][Full Text] [Related]
22. Cardiopulmonary hemodynamics and pharmacokinetics after hepatic intraarterial infusion of 5-fluorouracil (5-FU). An experimental study in the pig.
Andersson M; Domellöf L; Häggmark S; Johansson G; Reiz S; Gustavsson B
Cancer Chemother Pharmacol; 1988; 22(3):251-5. PubMed ID: 3409458
[TBL] [Abstract][Full Text] [Related]
23. RNA labelling with 3H-orotic acid and 3H-fluorouracil of rat liver tumour following transient hepatic arterial ischaemia.
Mack P; Tranberg KG; Strenram U; Jeppsson B; Widlus D; Bengmark S
Eur J Surg Oncol; 1988 Dec; 14(6):669-75. PubMed ID: 3192004
[TBL] [Abstract][Full Text] [Related]
24. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours.
McSheehy PM; Port RE; Rodrigues LM; Robinson SP; Stubbs M; van der Borns K; Peters GJ; Judson IR; Leach MO; Griffiths JR
Cancer Chemother Pharmacol; 2005 Feb; 55(2):117-28. PubMed ID: 15592719
[TBL] [Abstract][Full Text] [Related]
25. Vasopressin selectively increases 5-fluorouracil uptake by colorectal liver metastases following hepatic artery bolus infusion.
Dietz DW; Casillas S; Jones SC; Milsom JW
J Surg Res; 1998 Jul; 77(2):150-6. PubMed ID: 9733602
[TBL] [Abstract][Full Text] [Related]
26. [Experimental study of 5-FU + leucovorin therapy by continuous arterial infusion].
Mori T
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2838-41. PubMed ID: 2789495
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat.
Sawai Y; Yamaoka K; Ito T; Nakagawa T
Biol Pharm Bull; 1997 Dec; 20(12):1313-6. PubMed ID: 9448112
[TBL] [Abstract][Full Text] [Related]
28. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents.
Fujii S; Kitano S; Ikenaka K; Shirasaka T
Gan; 1979 Apr; 70(2):209-14. PubMed ID: 381088
[TBL] [Abstract][Full Text] [Related]
29. Locoregional application of 5-fluorouracil to the liver: alteration of pharmacokinetics and bone marrow toxicity in rats with thioacetamide-induced cirrhosis.
Aguiar JL; Berger MR; Frank N
Toxicol Lett; 1987 Apr; 36(2):181-8. PubMed ID: 3576649
[TBL] [Abstract][Full Text] [Related]
30. Effects of local microwave hyperthermia and 5-fluorouracil in treatment of experimental liver cancer.
Hugander A; Bolmsjö M; Hafström L; Gustavsson B
Anticancer Res; 1985; 5(3):281-5. PubMed ID: 4015042
[TBL] [Abstract][Full Text] [Related]
31. Relation between the incorporation of 5-fluorouracil into liver carcinoma and normal tissue RNA at hepatic arterial administration in the rat is altered by overnight starvation.
Roos G; Stenram U
J Surg Oncol; 1993 Aug; 53(4):231-4. PubMed ID: 7688058
[TBL] [Abstract][Full Text] [Related]
32. Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery. an autoradiographic study in the rat.
Mahteme H; Larsson B; Sundin A; Khamis H; Graf W
Eur J Cancer; 2004 Jan; 40(1):142-7. PubMed ID: 14687798
[TBL] [Abstract][Full Text] [Related]
33. Moment analysis of intestinal first-pass metabolism by portal-systemic concentration difference in single conscious rat using 5'-deoxy-5-fluorouridine and 5-fluorouracil as model drug system.
Sawai Y; Yamaoka K; Takemura A; Nakagawa T
J Pharm Sci; 1997 Nov; 86(11):1269-72. PubMed ID: 9383738
[TBL] [Abstract][Full Text] [Related]
34. 5-FU uptake in liver metastases after intravenous and intraperitoneal administration: an autoradiographic study in the rat.
Mahteme H; Larsson BS; Sundin A; Graf W
Anticancer Res; 1998; 18(2A):943-9. PubMed ID: 9615745
[TBL] [Abstract][Full Text] [Related]
35. Redistribution of blood flow in experimental hepatic tumours with noradrenaline and propranolol.
Burton MA; Gray BN
Br J Cancer; 1987 Nov; 56(5):585-8. PubMed ID: 3426921
[TBL] [Abstract][Full Text] [Related]
36. [An experimental study on portal infusion of 5-fluorouracil].
Ishida H; Iwama T; Nishioka Y; Endo S; Okubo Y; Imajo M; Otomo M; Mishima Y
Gan To Kagaku Ryoho; 1991 Aug; 18(11):1884-8. PubMed ID: 1877831
[TBL] [Abstract][Full Text] [Related]
37. Mapping the biodistribution and catabolism of 5-fluorouracil in tumor-bearing rats by chemical-shift selective 19F MR imaging.
Brix G; Bellemann ME; Haberkorn U; Gerlach L; Bachert P; Lorenz WJ
Magn Reson Med; 1995 Sep; 34(3):302-7. PubMed ID: 7500866
[TBL] [Abstract][Full Text] [Related]
38. The kinetics of uptake of 5-fluorouracil by rat liver.
Hsu LS
Br J Pharmacol; 1982 Nov; 77(3):413-7. PubMed ID: 7139195
[TBL] [Abstract][Full Text] [Related]
39. Biochemical modulation of intraperitoneal fluorouracil by allopurinol-the effect on an experimental adenocarcinoma in the liver.
Lindnér P; Carlsson G; Gustavsson B; Holmberg SB; Naredi P; Peterson A; Hafström L
Anticancer Res; 1994; 14(3A):847-52. PubMed ID: 8074485
[TBL] [Abstract][Full Text] [Related]
40. Modulation of 5-fluorouracil and 5-fluorouridine toxicity by membrane transport inhibitors in normal tissues of rats with liver adenocarcinoma.
Jakobsson B; el Hag IA; Erichsen C; Christensson PI; Jönsson PE; Stenram U
Anticancer Res; 1989; 9(2):285-90. PubMed ID: 2751255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
